Weight Loss Peptides Ranked: Retatrutide, Semaglutide, Tirzepatide, and MOTS-c

Weight loss pharmacology research encompasses several mechanistically distinct compound classes, each targeting different nodes in the energy homeostasis network. Ranking these compounds requires distinguishing between their evidence quality and their mechanistic specificity — the two dimensions that most determine research utility.

The incretin receptor agonist class (semaglutide, tirzepatide, retatrutide) is currently the highest-performing class by published efficacy data, with progressive improvements in weight reduction as additional receptor targets are added. This class works primarily through appetite suppression (GLP-1 receptor in hypothalamus and gut), insulin sensitization (GLP-1 + GIP receptors in pancreas and adipose), and thermogenesis (glucagon receptor in liver and brown adipose tissue).

The mitochondrial signaling class (MOTS-c, NAD+) addresses energy homeostasis from a different angle: AMPK activation and mitochondrial metabolic efficiency rather than appetite suppression. These compounds produce metabolic improvements in preclinical models through mechanisms more analogous to exercise than to pharmacological food intake suppression.

Growth hormone-related compounds (tesamorelin) address a specific subtype of adiposity — visceral fat — through the GH/IGF-1 axis, with evidence specific to clinical populations with pathological visceral fat accumulation (HIV lipodystrophy) that is distinct from general obesity research.

This mechanistic diversity means the compounds are more complementary than competitive from a research design perspective — each targets a different aspect of metabolic dysfunction.

The following table summarizes the five compounds across dimensions relevant to metabolic research protocol design.

For GLP-1 mechanism research: Semaglutide is the reference compound; use Retatrutide to add GIP + glucagon receptor contributions. For visceral fat research: Tesamorelin is the reference compound with FDA-validated data specifically in visceral adiposity. For AMPK/mitochondrial metabolic research: MOTS-c is the primary compound; no human data yet but strong animal evidence. For maximum weight reduction preclinical model: Retatrutide, which has the highest published weight loss efficacy of any compound in randomized trial data.

Retatrutide (LY3437943, Eli Lilly) holds the top position on the single dimension that is most directly relevant to weight loss research: published efficacy magnitude. The 2023 NEJM Phase 2 trial (NCT04881760, PMID 37352392) demonstrated a mean body weight reduction of 24.2% at 48 weeks in the 12 mg weekly group — the highest weight loss reported for any pharmacological intervention in a randomized controlled trial at the time of publication.

The trial also showed that weight loss curves had not plateaued at 48 weeks in the highest-dose groups, suggesting that longer treatment (as will be studied in the TRIUMPH Phase 3 program) may produce even greater reductions. By comparison, the weight loss trajectories in semaglutide STEP trials showed clear plateaus by 52-68 weeks; tirzepatide SURMOUNT curves flattened somewhat later. The still-descending retatrutide curves at trial end are consistent with the glucagon receptor component contributing ongoing thermogenic effects that compound over time.

The dose-response data from the Phase 2 trial is particularly useful for research protocol design. Six active dose groups (1 mg through 12 mg weekly) provide a complete dose-response curve: 1 mg/wk (-8.7%), 2 mg/wk (-17.1%), 4 mg/wk (-17.5%), 8 mg/wk (-22.8%), 12 mg/wk (-24.2%) versus placebo (-1.6%). The full dose-response architecture enables researchers to select the dose that produces the metabolic phenotype appropriate for their research question rather than defaulting to the highest dose for every experiment.

Tirzepatide (Mounjaro/Zepbound, Eli Lilly) and its receptor profile represent the dual GLP-1/GIP agonist class — the most clinically advanced and best-characterized weight loss compound class after FDA approval for both type 2 diabetes (2022) and obesity (2023). For researchers, the FDA approval status means that human pharmacokinetic data, Phase 3 safety and efficacy data across diverse populations, and post-marketing surveillance data are all available in the public literature — providing a reference dataset that Retatrutide (still in Phase 3) lacks.

The SURMOUNT-1 Phase 3 trial (2,539 participants, 72 weeks) is the landmark obesity efficacy dataset for this compound class, demonstrating 20.9% mean weight loss at the 15 mg dose — confirming and slightly exceeding Phase 2 estimates. SURMOUNT-2 in T2DM populations, SURMOUNT-3 in run-in responder populations, and SURMOUNT-4 in maintenance populations together provide the most comprehensive human metabolic intervention dataset available for any compound in this class.

For researchers designing studies that require comparison to a well-characterized approved benchmark, tirzepatide-class dual agonism provides the reference standard against which retatrutide's additional glucagon receptor activity can be compared. The difference between tirzepatide outcomes and retatrutide outcomes in parallel preclinical experiments isolates the glucagon receptor contribution — a scientifically important attribution that the sequential clinical trial record cannot provide.

Semaglutide (Ozempic/Wegovy, Novo Nordisk) represents pure GLP-1 receptor agonism — the mechanistic baseline against which all dual and triple receptor agonists should be compared. Its 14.9% mean weight loss in STEP 1 (2.4 mg weekly, 68 weeks) established the GLP-1-only benchmark that tirzepatide and retatrutide subsequently exceeded.

For researchers, semaglutide's value is not its weight loss efficacy (which is the lowest of the three GLP-1-containing compounds) but its mechanistic purity — any effect observed with semaglutide is attributable to GLP-1 receptor agonism alone. When comparing semaglutide to tirzepatide in parallel experiments, any difference in outcome is attributable to GIP receptor addition. Comparing tirzepatide to retatrutide isolates the glucagon receptor contribution. This systematic receptor attribution framework makes the three-compound comparison an exceptionally powerful research design for dissecting the relative contribution of each receptor to metabolic outcomes.

The SELECT cardiovascular outcomes trial (PMID 38092489) showed that semaglutide reduced major adverse cardiovascular events by 20% in overweight and obese patients without diabetes — establishing that GLP-1 receptor agonism produces cardiovascular benefit independent of glucose lowering. This cardiovascular benefit finding adds an important dimension to metabolic research design: compounds targeting GLP-1 receptors may affect cardiovascular endpoints as well as weight, which requires experimental designs that account for both outcomes.

Tesamorelin (Egrifta, Theratechnologies) is a stabilized GHRH (growth hormone-releasing hormone) analog that produces sustained GH release through stimulation of the pituitary GHRH receptor. Its FDA approval in 2010 for HIV-associated lipodystrophy (a condition of pathological visceral fat accumulation) makes it the most clinically validated GHRH analog available for research.

Tesamorelin's mechanistic contribution to weight loss research is visceral fat specificity — published clinical trials demonstrate 15-20% reductions in visceral adipose tissue area (measured by CT scan) with minimal effect on subcutaneous fat. This visceral fat selectivity is mechanistically important: visceral adipose tissue has higher metabolic activity, greater insulin resistance contribution, and stronger cardiovascular risk association than subcutaneous fat, making it a more functionally significant target in metabolic disease research.

The GH/IGF-1 axis mechanism is distinct from all three GLP-1-related compounds: tesamorelin does not affect appetite, gastric emptying, or GLP-1 signaling pathways. Its adipose-specific lipolysis effect is mediated through GH receptor signaling in visceral adipocytes, driving fatty acid mobilization independent of the caloric restriction mechanisms of GLP-1 agonists. For researchers studying visceral adiposity specifically — rather than total body weight — tesamorelin is the most appropriate primary compound.

Published Phase 3 data (Falutz et al., 2010, *NEJM*) showed that tesamorelin reduced visceral fat area by approximately 18% over 26 weeks in HIV-lipodystrophy patients versus 2% with placebo, with statistically significant improvements in triglycerides and IGF-1 levels. This data provides the most direct human evidence of GHRH analog effects on regional adiposity.

MOTS-c ranks fifth on evidence weight but is mechanistically the most distinct compound in this comparison — and the most relevant for researchers studying the exercise mimetic dimension of metabolic biology rather than pharmacological appetite suppression.

MOTS-c is a 16-amino acid mitochondria-encoded microprotein that, when released from mitochondria under metabolic stress, translocates to the nucleus where it activates AMPK and regulates gene expression programs that substantially overlap with those induced by aerobic exercise. Published animal research (Lee et al., 2015, *Cell Metabolism*; Kim et al., 2021, *Nature Communications*) demonstrates that MOTS-c administration in rodents improves insulin sensitivity, reduces high-fat diet-induced obesity, and extends lifespan in aged animals — all through AMPK-mediated metabolic reprogramming rather than appetite suppression.

The mechanistic contrast with GLP-1 agonists is complete: GLP-1 class compounds reduce caloric intake (appetite suppression + delayed gastric emptying); MOTS-c increases caloric efficiency and metabolic rate (AMPK-driven). In preclinical models, MOTS-c-treated animals lose body weight while maintaining or increasing food intake — the opposite of GLP-1-driven weight loss. This mechanistic divergence makes MOTS-c the ideal comparator for studies designed to distinguish appetite-driven from metabolism-driven weight loss.

MOTS-c has no published human clinical trial data as of mid-2026. The animal evidence is strong and mechanistically coherent, and MOTS-c levels are measurable and declining with age in human blood samples, but the human metabolic efficacy evidence remains to be established.

The five compounds in this ranking are most useful to researchers when treated as tools for mechanistic attribution rather than as competing alternatives for the same research question.

To isolate GLP-1 receptor contribution: Semaglutide alone is the reference. To isolate GIP receptor addition: Tirzepatide minus semaglutide effect size. To isolate glucagon receptor addition: Retatrutide minus tirzepatide effect size. To study thermogenesis-driven weight loss: Retatrutide's glucagon component; design experiments measuring energy expenditure as a primary endpoint. To study exercise-pathway metabolic reprogramming: MOTS-c is the primary compound; compare AMPK activation markers and gene expression to aerobic exercise controls. To study visceral fat remodeling: Tesamorelin, with CT-measured visceral adipose area as the primary endpoint.

The most informative preclinical metabolic studies use two or more of these compounds in parallel experimental arms, enabling direct mechanistic comparison rather than single-compound description. The sequential clinical trial record cannot provide this parallel comparison; preclinical research can.

All compounds described are research-use-only materials. Retatrutide, MOTS-c, and tesamorelin are not approved for general obesity treatment (tesamorelin is FDA-approved for HIV lipodystrophy only). Researchers designing protocols should consult primary published literature for dose selection and administration routes appropriate to their specific model.